Method and System for Diagnosis of \u3cem\u3eLawsonia Intracellularis\u3c/em\u3e by Stills, Harold F., Jr. et al.
University of Kentucky
UKnowledge
Microbiology, Immunology and Molecular Genetics
Faculty Patents
Microbiology, Immunology, and Molecular
Genetics
9-1-2015
Method and System for Diagnosis of Lawsonia
Intracellularis
Harold F. Stills Jr.
University of Kentucky, harold.stills@uky.edu
David W. Horohov
University of Kentucky, dwhoro2@uky.edu
Allen E. Page
University of Kentucky, allen.e.page@gmail.com
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/microbio_patents
Part of the Medical Immunology Commons, and the Medical Microbiology Commons
This Patent is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at UKnowledge. It has been accepted
for inclusion in Microbiology, Immunology and Molecular Genetics Faculty Patents by an authorized administrator of UKnowledge. For more
information, please contact UKnowledge@lsv.uky.edu.
Recommended Citation
Stills, Harold F. Jr.; Horohov, David W.; and Page, Allen E., "Method and System for Diagnosis of Lawsonia Intracellularis" (2015).
Microbiology, Immunology and Molecular Genetics Faculty Patents. 1.
https://uknowledge.uky.edu/microbio_patents/1
c12) United States Patent 
Stills, Jr. et al. 
(54) 
(71) 
(72) 
(73) 
( *) 
(21) 
(22) 
(65) 
(60) 
(51) 
(52) 
(58) 
(56) 
METHOD AND SYSTEM FOR DIAGNOSIS OF 
LAWSON/A INTRACELLULARIS 
Applicant: University of Kentucky Research 
Foundation, Lexington, KY (US) 
Inventors: Harold F. Stills, Jr., Lexington, KY 
(US); David W. Horohov, Lexington, 
KY (US); Allen E. Page, Lexington, KY 
(US) 
Assignee: University of Kentucky Research 
Foundation, Lexington, KY (US) 
Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 0 days. 
Appl. No.: 13/676,898 
Filed: Nov. 14, 2012 
Prior Publication Data 
US 2013/0164765 Al Jun. 27, 2013 
Related U.S. Application Data 
Provisional application No. 61/560,275, filed on Nov. 
15, 2011. 
Int. Cl. 
GOJN33/554 
GOJN33/569 
GOJN33/53 
GOJN33/68 
U.S. Cl. 
(2006.01) 
(2006.01) 
(2006.01) 
(2006.01) 
CPC ...... GOJN 3316893 (2013.01); GOJN 33156911 
(2013.01); GOJN 2469/20 (2013.01) 
Field of Classification Search 
CPC .................... GOlN 33/56911; GOlN 2469/20; 
C12Q 1/689; C07K 14/195 
See application file for complete search history. 
References Cited 
U.S. PATENT DOCUMENTS 
7,029,683 B1 * 
2006/0024696 A1 * 
4/2006 Panaccio eta!. ........... 424/234.1 
2/2006 Kapur eta!. ...................... 435/6 
OTHER PUBLICATIONS 
Ion Exchange Chromatography (IEC), http://www.proteinchemist. 
com/tutorial/iec.html, accessed Jan. 28, 2014.* 
Bollag, Ion-Exchange Chromatography (Chapter 2), Methods in 
Molecular Biology, 1995; 36: 11-22.* 
http://www. gelifesciences. com/webapp/wc s/ stores/ serv let/ 
productByld/en/GELifeSciences/ 17070901; accessed Mar. 25, 
2014.* 
Boesen, H.T., Jensen, T.K., Brees, D.J., Sondhoff, A.H., Kluge, J.P., 
Andreasen, C.B. And Brown, C. M. (2005) Evaluation of a novel 
enzyme-linked immunosorbent assay for serological diagnosis of 
porcine proliferative enteropathy. Vet. Microbiol. 109, 105-112. 
Guedes, R.M., Gebhart, C.J., Guedes, R.M., Gebhart, C.J., Deen, J. 
And Winkelman, N.L. (2002a) Serologic follow-up of a repopulated 
swine herd after an outbreak of proliferative hemorrhagic 
enteropathy. Can. J. vet. Res. 66, 258-263. 
I IIIII 1111111111111111111111111111111111111111111111111111111111111 
US009121856B2 
(10) Patent No.: 
(45) Date of Patent: 
US 9,121,856 B2 
Sep.1,2015 
Guedes, R.M., Gebhart, C.J., Herbst, W., Hertrampf, B., Schmitt, T., 
Weiss, R. And Baljer, G. (2002b) Validation of an immunoperoxidase 
monolayer assay as a serologic test for porcine proliferative 
enteropathy. J. vet. Diag. Invest. 14, 528- 530. 
Jacobson, M., Aspan, A., Jones, G.F., Ward, G.E., Murtaugh, M.P., 
Lin, G. And Gebhart, C.J. (2004) Routine diagnostics of Lawsonia 
intracellularis performed by PCR, serological and post mortem 
examination, with special emphasis on sample preparation methods 
for PCR. Vet. Microbiol. 102, 189-201. 
Kroll, J.J., Eichmeyer, M.A., Lavoie, J.P., Drolet, R., Parsons, D., 
Leguillette, R., Sauvageau, R., Shapiro, J., Houle, L., Halle, G., 
Gebhart, C.J. (2005) Lipopolysaccharide-based enzyme-linked 
immunosorbent assay for experimental use in detection of antibodies 
to Lawsonia intracellularis in pigs. Clin. Diagn. Lab. Immunol. 12, 
693-699. 
Page, A. E., Slovis, N.M., Gebhart, C.J., Wolfsdorf, K., Mapes, S.M. 
AndPusterla, N. (20 11 b) Serial use of serologic assays and fecal PCR 
assays to aid in identification of subclinical Lawsonia intracellularis 
infection for targeted treatment of Thoroughbred foals and 
weanlings. J. Am. Vet. Med. Assoc. 238, 1482-1489. 
Page, A.E., Stills, H.F., Chander, Y., Gebhart, C.J., Horohov, D.W. 
(20 11) Adaptation and validation of a bacteria-specific enzyme-
linked immunosorbent assay for determination of farm-specific 
Lawsonia intracellularis seroprevalence in central Kentucky Thor-
oughbreds. Equine Veterinary Journal43 (Suppl. 40) 25-31. 
Pusterla, N., Higgins, J.C. et al. (2008a) Epidemiological survey on 
farms with documented occurrence of equine proliferative 
enteropathy due to Lawsonia intracellularis. Vet. Rec. 163, 156-158. 
Sorensen, K. And Brodbeck, U. (1986) Assessment of coating-effi-
ciency in ELISA plates by direct protein determination. J. Immunol. 
Methods 95, 291-293. 
Watarai, M., Yamato, Y. eta!. (2004) Enzyme-linked immunosorbent 
assay to detect Lawsonia intracellularis in rabbits with proliferative 
enteropathy. J. vet. med. Sci. 66, 735-737. 
(Continued) 
Primary Examiner- Gary Nickol 
Assistant Examiner- Lakia Tongue 
(74) Attorney, Agent, or Firm- Stites & Harbison PLLC; 
Mandy Wilson Decker 
(57) ABSTRACT 
A method, system, and kit are provided for diagnosing L. 
intracellularis infection or exposure in a subject. The method 
includes purifYing whole L. intracellularis from host cells 
and host debris produced in or on a suitable medium and 
adhering the purified whole L. intracellularis on a suitable 
material to form an antigen substrate for determining whether 
a subject produces L. intracellularis-specific antibodies 
against the antigen to thereby indicate L. intracellularis expo-
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METHOD AND SYSTEM FOR DIAGNOSIS OF 
LAWSON/A INTRACELLULARIS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
Enzyme-linked immunosorbent assay (ELISA) for detec-
tion of L. intracellularis-specific antibodies have been previ-
ously developed for the pig and rabbit (Watarai et a!. 2004; 
Boesen eta!. 2005; Kroll eta!. 2005; Wattanaphansak eta!. 
2008). 
SUMMARY OF THE INVENTION 
The present invention is directed to a novel method for 
This application claims the benefit of Provisional Applica-
tion Ser. No. 61/560,275, filed Nov. 15, 2011 herein incorpo-
rated by reference. 
FIELD OF THE INVENTION 
The presently-disclosed subject matter relates to methods 
and systems for use in the diagnosis of Law sonia intracellu-
laris infection in a subject. In particular, the presently-dis-
closed subject matter relates to an enzyme-linked immuno-
absorbent assay (ELISA) for diagnosing Lawsonia 
intracellularis infection and exposure in a subject. 
10 detecting the presence of Lawsonia intracellularis-specific 
antibodies for the diagnosis of Lawsonia intracellularis 
exposure or infection. The present method and system may 
also be used for evaluating the efficacy of a vaccine. The 
presently disclosed subject matter overcomes sensitivity and 
15 specificity issues associated with prior techniques for evalu-
ating Lawsonia intracellularis exposure and infection includ-
ing those described above in the Background of the Invention 
section. The present method and system can be used for 
subjects including but not limited to farm animals, such as 
BACKGROUND OF THE INVENTION 20 horses (including race horses) and swine. 
One unique aspect of the present method and system for 
detecting Lawsonia intracellularis exposure or infection 
includes a process in which whole L. intracellularis cells, are 
purified for use as an antigen in the ELISA. As a result, the 
Exposure to pathogens cause illness and even death to 
living organisms such as humans, animals and plants. There 
are numerous techniques used to diagnose pathogen infec-
tions and exposure. 
One pathogen of importance to mammals is the bacterium, 
L. intracellularis. L. intracellularis is an obligate intracellu-
lar, Gram-negative rod, is the causative agent of proliferative 
enteropathy (Lawson and Gebhart 2000). L. intracellularis is 
viewed as an emerging cause of proliferative enteropathy in a 
variety of mammalian species (Drolet eta!. 1996; Hotchkiss 
eta!. 1996), including horses (Williams eta!. 1996; Cooper et 
25 present method and system uses whole purified Lawsonia 
intracellularis in contrast to prior techniques which are 
directed to identifying the presence of a Law sonia intracel-
lularis amongst host cells and host cell debris due to a lack of 
complete purification of the L. intracellularis. In various spe-
a!. 1997; Frank et a!. 1998; Brees et a!. 1999), where the 
bacteria causes equine proliferative enteropathy (EPE). 
30 cific forms of the present method and system, the purified L. 
intracellularis, e.g. bacteria, is a chromatography-purified 
whole L. intracellularis. As will be recognized by those of 
ordinary skill in the art, it can be useful to monitor a particular 
subject over time using the methods and systems described 
35 herein, i.e., conducting multiple diagnostic tests at different Clinical signs of EPE, usually seen in weanlings or young 
yearlings (Frank eta!. 1998; Brees eta!. 1999; Lavoie eta!. 
2000; Schumacher et a!. 2000; Frazer 2008), include anor-
exia, fever, lethargy, depression, peripheral edema caused by 
hypoproteinemia/hypoalbuminemia, weight loss, colic and 
diarrhea. In addition, thickened small intestine detected by 40 
abdominal ultrasound is considered highly suggestive ofEPE 
when accompanied by compatible clinical signs. Commer-
cially available ante mortem tests for EPE include fecal L. 
intracellularis-specific polymerase chain reaction (PCR) and 
the serum immunoperoxidase monolayer assay (IPMA), both 45 
of which have been adapted from their use in pigs where the 
tests are highly specific; sensitivity is reported to be high for 
the IPMA (Guedes eta!. 2002a,b) but variable for faecal PCR 
(Herbst eta!. 2003; Jacobson eta!. 2004). 
time points. 
The present invention, in one form thereof, relates to a 
method for diagnosing L. intracellularis exposure or infec-
tion in a subject. The method includes acquiring a blood 
sample from a subject and processing that blood sample using 
centrifugation which separates serum from whole blood cells 
to form an isolated sample. The isolated sample is analyzed 
for the presence of L. intracellularis-specific antibodies using 
an ELISA and the subject is diagnosed as having a L. intra-
cellularis infection or exposure if the presence of L. intrac-
ellularis-specific antibodies are detected when analyzing the 
isolated sample. For analysis of the isolated sample, L. intra-
cellularis whole cells are processed and purified using cen-
trifugation followed by chromatography. 
The present invention, in another form thereof, relates to a 
method for evaluating effectiveness of a vaccine against a L. 
intracellularis infection in a subject. The method includes 
administering a test vaccine to a subject and subsequently 
acquiring a blood sample from the subject. The blood sample 
is processed using centrifugation which separates serum from 
whole blood cells form an isolated sample. The isolated 
sample is analyzed for presence of L. intracellularis-specific 
antibodies. The vaccine is determined to be effective at elic-
Although the epidemiology of EPE is uncertain, it is 50 
believed that transmission occurs through the ingestion of L. 
intracellularis-contaminated fecal material from wild or 
domestic animals (Pusterla eta!. 2008b ). While most cases of 
EPE typically occur in the fall and early winter (Frazer 2008; 
Page et a!. 2011 b), the reason for this seasonal predilection 55 
has not yet been determined. One possibility is the known 
susceptibility of weanlings to this infection and weaning typi-
cally occurs during this time of year (Frazer 2008). Another 
possibility would be that the environmental conditions at that 
time favor transmission by increasing exposure burdens. 
Previous work on the detection of L. intracellularis-spe-
cific antibodies on specific farms demonstrated seropreva-
lences ranging from 33.8 to 45.5% on two California farms 
(Pusterla et a!. 2008a) and up to 60% on a Kentucky farm 
(Page eta!. 2011 b), utilizing the IPMA method. A large scale, 65 
recent study, detailed within, found that seroprevalence on 
some equine farms actually approaches 1 00%. 
iting an immune response if L. intracellularis-specific anti-
60 bodies are detected when analyzing the isolated sample and 
the subject does not exhibit symptoms of L. intracellularis 
infection or signs of clinical disease. 
In one further specific form of the method for evaluating 
effectiveness of a vaccine, the method further includes expos-
ing a subject to a L. intracellularis after the vaccine has been 
administered to the subject and the subject has had sufficient 
time to develop an immune response to the vaccine but before 
US 9,121,856 B2 
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acquiring the blood sample from the subject. Effectiveness of 
the vaccine is determined if the subject blood sample has 
detectable amounts of L. intracellularis-specific antibodies 
and remains free of signs of clinical disease. 
The present invention, in another form thereof, relates to a 
method for diagnosing L. intracellularis infection or expo-
sure in a subject. The method includes purifying whole L. 
intracellularis from host cells and host debris produced in or 
on a suitable medium. The purified L. intracellularis is 
adhered on a suitable material to form an antigen substrate for 10 
determining whether a subject produces L. intracellularis 
specific-antibodies against the antigen and thereby indicate a 
L. intracellularis exposure or infection in the subject. 
The pathogen may be purified from host cells and host 
debris using centrifugation followed by ion-exchange chro- 15 
matography. The suitable material upon which the purified L. 
intracellularis is adhered may be an enzyme-linked immun-
osorbent assay (ELISA) plate. In one specific form, the 
method may include introducing a serum sample from a sub-
ject to the antigen substrate to determine whether the serum 20 
contains L. intracellularis-specific antibodies against the 
antigen. The serum may be produced from centrifugation of a 
blood sample taken from the subject. 
The present invention, in another form thereof, relates to a 
kit for diagnosing pathogen infection or exposure in a subject. 25 
The kit includes purified, whole pathogen adhered to a suit-
able material to form an antigen substrate. The antigen sub-
strate is adapted to be used to screen serum from a subject for 
L. intracellularis-specific antibodies against the antigen, to 
thereby indicate L. intracellularis exposure or infection in the 30 
subject. Advantageously, the purifiedL. intracellularis is pro-
duced by centrifugation of pathogen host cells and host debris 
followed by ion-exchange chromatography. Further, in one 
specific form, a suitable material is an ELISA plate. 
The present invention, in another form thereof relates to a 35 
method for diagnosing L. intracellularis infection or expo-
sure in a subject. The method included acquiring a serum 
sample from a subject and introducing the serum sample to an 
antigen substrate comprising purified L. intracellularis 
adhered to a suitable medium. The purified L. intracellularis 40 
is produced from host cells and host debris. Presence of L. 
intracellularis-specific antibodies are detected in the serum 
against the antigen substrate, thereby indicating pathogen 
exposure or infection in the subject. 
Exemplary conditions and reagents that can be used in 45 
some embodiments of the present method and system include 
the ELISA methods disclosed herein. A carbonate buffer can 
be used as a coating buffer. The antigen can be provided at a 
concentration of about 2.5 micrograms/ml, and the plate/ 
antigen can incubate overnight at about 4 degrees C. PBS with 50 
Tween can be used as the ELISA wash, and polyvinyl alcohol 
can be used as the blocking buffer. The sample serum dilution 
can be about 1:100, and the sample incubation can be at room 
temperature for about 1 hour. The antibodies can be mouse 
anti-horse conjugated with HRP, and the anti IgG incubation 55 
can be at room temperature for about 1 hour in the dark. In 
some embodiments anti-IgM can be used. The substrate can 
be TMB (3,3',5,5'-tetra-methylbenzidine). A standard curve 
can be generated from known IPMA titer, and ELISA units 
(EU) can be determined on a continuous scale, allowing for a 60 
sensitive and specific measurement. The ELISA procedure 
can be modified to incorporate other species-specific reagents 
such that the ELISA can test samples originating from a 
variety of other species including, but not limited to, swine, 
hamsters, rabbits, mice, rats, non-human primates, humans, 65 
raccoons, birds and insects. It is important to note that the 
present ELISA can be easily adapted for use in a variety of 
4 
other species (i.e. not just horses), which will be readily 
apparent to those of ordinary skill in the art. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a plot relating enzyme-linked immunosorbent 
assay (ELISA) units (EU) values for nonchallenged weanling 
controls and L. intracellularis-challenged weanlings as well 
as clinical EPE cases in which dashed bar represents 55 EU, 
of the cut-off for positive samples. 
FIG. 2 is a plot relating ELISA units to weanlings overtime 
in which all studied time points from those weanlings 
remained seronegative (<55 Enzyme-linked immunosorbent 
assay (ELISA) units (EU) for the entire study and those that 
seroconverted at any point;;,;55 EU) during the study period. 
Each colunm for the study horses represents an individual 
horse. Dashed bar represents 55 EU. 
FIG. 3 is a graph depicting monthly percentage of previ-
ously seronegative horses that seroconverted (55 Enzyme-
linked immunosorbent assay (ELISA) units ((EU) or greater) 
during a given month and total number of seropositive horses. 
FIG. 4 is a chart depicting monthly distribution of positive 
enzyme-linked immunosorbent assay (ELISA) results 
reported as ranges of ELISA units (EU). 
FIG. 5 is a plot showing monthly seroconversions for 
groups (confirmed, suspected, none) of farms based on recent 
equine proliferative enteropathy (EPE) history. 
DETAILED DESCRIPTION 
The present method and system will now be described with 
reference to specific experiments demonstrating the efficacy 
of the present method and system in diagnosing L. intracel-
lularis infection or exposure. However, the following 
examples and experiments do not limit the scope of the 
present disclosure and variations to the methods and experi-
ments described below can be modified in accordance with 
the understanding of one of ordinary skill in the art. 
Materials and Methods 
Farm Selection and Information Gathering 
A total of 25 Thoroughbred farms were recruited for par-
ticipation in a study using various methods to test efficacy of 
the present methods. Farms provided information regarding 
EPE cases in the preceding 3 years. These data were used to 
classify farms as either having confirmed cases of EPE, sus-
pected but unconfirmed cases of EPE, or no recent cases of 
EPE. Farms were considered to have had confirmed EPE 
cases if they had one or more weanlings with clinical signs 
compatible with EPE, hypoproteinaemia and hypoalbumin-
emia, and either a concurrent positive faecal PCR or serum 
IPMA titer result (1:60 or greater) in the preceding 3 years. 
For the purpose of this study, compatible clinical signs for 
EPE were anorexia, fever, lethargy, depression, dependent 
edema, rapid weight loss, colic and diarrhea. Farms were 
considered to have had suspected EPE cases if they had one or 
more weanlings with signs compatible with EPE, but neither 
a positive faecal PCR nor positive serum IPMA titer result 
(1:60 or greater). Farms were considered to have had no 
recent history of EPE if there were no horses with clinical 
signs ofEPE within the preceding 3 years. 
After the conclusion of the study, all participating farms 
were requested to complete a questionnaire regarding EPE 
cases on the farm during the study period. Based on this 
information, farms were classified for the study period into 
the 3 categories as above. 
US 9,121,856 B2 
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Study Period 
The study period began Aug. 16, 2010 and concluded Jan. 
5, 2011. For some farms, an optional sample collection period 
from 31 Jan. to 2 Feb. 2011 was included in the study due to 
6 
0.01 M. Phosphate buffer, is applied to a low pressure liquid 
chromatography colunm (2.5 cmx30 em) containing DEAE-
Sepharose CL-6B equilibrated with 0.01 M. Phosphate 
a large increase in the number of seropositive samples in 5 
January. Samples were collected from the farms once during 
buffer, pH 6.8. The colunm is washed with 5 volumes of0.01 
M. Phosphate buffer, pH 6.8. The buffer is then changed 
sequentially to 0.01 M. Phosphate buffer, pH 6.8 with 0.1 M 
a 3 day period every 4 weeks. 
Horses 
Although some farms housed non-Thoroughbred horses, 
only Thoroughbred horses were included in the study. All 10 
horses in the study were born during the 2010 foaling season 
and weaned by November 2010. Farms were requested to 
provide a list of all 2010 horses present on the farm in early 
August 2010. If a farm had 14 or fewer 2010 horses at this 
time, all horses were included in the study. For those farms 15 
with 15 or more horses present in early August, 15 horses 
were chosen randomly to participate (except for Farm 19, 
from which all 16 horses were included in the study at the 
farm's request). Randomization was achieved by assigning 
each horse a sequential number and utilizing a random num- 20 
ber generator (Microsoft Excel) to select the 15 horses for 
inclusion in the study. Each horse included in the study was 
assigned a unique 3 digit identification number for ease of 
results tracking, as well as maintaining anonymity. 
NaCI, 0.01 M. Phosphate buffer, pH 6.8 with 0.15 M NaCI, 
and 0.01 M. Phosphate buffer, pH 6.8 with 0.2 M NaCI and 
the eluted protein peaks collected. The eluted material is 
concentrated by centrifugation (6,500 g for 60 minutes at 4° 
C.) if necessary and resuspended in PBS with 0.02% NaN3 . 
Referring now to one specific purification process, por-
cine-origin L. intracellularis was obtained from cell culture 
(Lawson et a!. 1993) and purified using diethy laminoethy I 
(DEAE) colunm chromatography, which allowed the bacte-
rium to be eluted as a whole organism. The presence of L. 
intracellularis in the eluate was verified microscopically 
using Gimenez stain, in addition to PCR for L. intracellularis, 
as previously described (Jones eta!. 1993). Additionally, no 
other bacteria were present following aerobic and anaerobic 
culture, as well as Gram staining. The pooled purified bacte-
rial eluate with sodium azide was kept refrigerated ( 4° C.). 
Quantification of the purified bacterial protein performed 
using the bicinchoninic acid (BCA) method (Sorensen and 
Sample Collection and Handling 
Once every 4 weeks, a 10 ml sample of whole blood was 
collected into individually labeled, sterile, red-top 10 ml 
blood tubes via jugular venipuncture. Samples were submit-
ted and held at centralized laboratories at 4 o C. for less than 24 
h before they were collected and transported to the Maxwell 
H. Gluck Equine Research Center at the University of Ken-
tucky. Upon arrival, samples were immediately centrifuged at 
800xg for 10 min. Serum was transferred to tubes labeled 
with the month and a unique 3 digit code assigned to its horse 
and frozen at -20° C. until analyzed. 
For various reasons, including public sale, private sale or a 
horse being returned to its owner, a number of blood samples 
were omitted from the study. As such, data from any horses 
that left the study prior to November were completely 
excluded from the data set. Horses remained in the study even 
if one or more samples were not collected after October. 
Serum samples obtained from 6 Law sonia intracellularis-
challenged weanlings and 15 uninfected controls were 
included for the validation of the ELISA, with information 
regarding the challenge reported elsewhere (Page et a!. 
2011a). 
Lawsonia intracellularis-Specific Immunoperoxidase 
Monolayer Assay 
The IPMA method for determining L. intracellularis-spe-
cific antibody titers was performed as previously described 
(Guedes eta!. 2002b ). 
Purification of L. intracellularis 
L. Intracellularis is purified using centrifugation and ion-
exchange chromatography. Generally speaking ion-exchange 
chromatography involves the process of separating polar 
(charged) materials (compounds, particulates, etc.) on the 
basis of the charges carried by solute molecules. Materials to 
be separated are adhered to the reversibly charged insoluble 
matrix of the exchange material and then sequentially eluted 
by altering either the solvent pH or ionic concentration. In this 
specific case DEAE serves as the ion exchange media to 
which the centrifuged bacteria is adhered and then purified by 
elution with increasing buffer salt (NaCI) concentrations. 
Specifically, the bacteria are initially isolated from cellular 
debris initially by low speed centrifugation ( 400-600xg) to 
remove cellular debris followed by high speed centrifugation 
(6,500xg) to pellet the bacteria. The bacteria, suspended in 
25 Brodbeck 1986). 
Law sonia intracellularis-Specific Enzyme-Linked Immu-
nosorbent Assay 
The ELISA was based on previously described methods 
(Wattanaphansak eta!. 2008) with respect to starting concen-
30 trations of reagents and a checkerboard titration scheme, as 
described elsewhere (Kroll eta!. 2005; Wattanaphansak eta!. 
2008). Factors influencing background were minimized 
using previously described methods (Wattanaphansak et a!. 
2008). From this, it was found that serum dilutions of 1:100 
35 produced the most consistent results with minimal back-
ground. Further, based on this approach, the optimum con-
centration of antigen was 2.5 flg/ml and the use of a polyvinyl 
alcohol block was superior to 5 or 10% skim milk. 
The ELISA plates (Immunolon 1 b Flat Bottom Microtiter 
40 plates) were coated with 2.5 flg/ml of purified L. intracellu-
laris in carbonate buffer, then covered with Parafilm-M and 
allowed to sit overnight at 4 o C. After plates incubated over-
night, they were washed 3 times with phosphate-buffered 
saline with 0.05% Tween-20 (PBST) using an ELISA plate 
45 washer (MW 96/384 ). The coated plates were then blotted dry 
before adding 200 fll/well of blocking buffer (polyvinyl alco-
hol [Mowiol 6-98] 1% [ w/v] in distilled water) for 1 hour at 
room temperature. After blocking, the plates were washed 3 
times, as above. Sera were diluted at 1:100 in blocking buffer 
50 and added (1 00 fll) to duplicate wells. Plates were then incu-
bated at room temperature for 1 h. Duplicate, serially diluted 
(1 :60 through 1:3840) serum samples from a weanling exhib-
iting clinical signs compatible with EPE, including anorexia, 
weight loss and dependentedema, was used to generate a 
55 standard curve. This weanling tested positive repeatedly at 
1:1920 using the IPMA method. Negative control samples 
included serum from repeatedly L. intracellularis antibody-
negative weanlings along with a duplicate sample of 100 fll 
fetal equine serum diluted 1:100. After 1 h incubation with 
60 diluted test and control sera, the plate was washed 3 times and 
100 ml of murine anti horse IgG (1:4000) conjugated with 
horseradish peroxidase (HRP) was added to each well. The 
plate was then incubated in the dark for 1 hat room tempera-
ture before being washed 3 times. To each well was then 
65 added 100 fll of3,3',5,5'-tetra-methylbenzidine (TMB) solu-
tion (SureB!ue TMB Microwell Peroxidase substrate) for 2 
min before the reaction was stopped with TMB Stop solution. 
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Absorbance at 450 run was read within 5 min using an ELISA 
plate reader (Benchmark plus). Results from the test sera 
were converted to ELISA units (EU) utilizing a linear trend 
line from the standard curve generated from each plate. A 
coefficient of determination (r) oh0.90 was required for the 
plate to be considered valid (Kroll et a!. 2005). 
A positive cut -off of 55 EU or greater was utilized based on 
nonchallenged weanlings having an average of 33 EU and a 
standard deviation of7 EU (Page eta!. 2011a); these samples 
repeatedly tested negative via IPMA. By setting the cut-off at 10 
55 EU, this value is 3 s.d. units above the negative control 
averages and represents the upper limit of a 99% confidence 
interval. 
Evaluation of Assay Repeatability 
Twenty-four samples were selected for the ELISA repeat- 15 
ability test. These represented a variety of negative (<55 EU), 
low (55-119 EU), mid (120-239 EU) and high (-240 EU) 
samples. For intra-assay repeatability, 3 replicates of each 
sample were performed on the same plate. For inter-assay 
repeatability, 3 replicates of each sample were run on dupli- 20 
cate plates on different days. Coefficient of variation 
(CV=s.d./meanx100%) of the 3 replicates from each test 
were evaluated. In addition, CV's of the standard curve opti-
cal densities (ODs) from each plate was evaluated. 
8 
at one or more time points. The monthly percentage of pre-
viously seronegative horses that seroconverted during a given 
month and the accruing totals are shown in FIG. 3. Overall, 
there was a steady increase in the number of seropositive 
horses over time 
TABLE 1 
Seroprevalence by farm according to previous EPE history and 
equine proliferative enteropathy (EPE) status during the study period 
Farm 
2 
4 
7 
8 and 9 
10 
11 
History 2010 
of foaling 
previous season 
EPE cases EPE cases 
No No 
Suspected No 
Confirmed Confirmed 
Confirmed No 
Confirmed No 
Confirmed Confirmed 
No No 
Confirmed No 
Confirmed Confirmed 
No No 
Total 
ELISA Total No. 
positive horses 
horses sampled Sera prevalence 
11 15 73.3% 
15 20.0% 
9 9 100.0% 
7 12 58.3% 
10 15 68.7% 
9 10 90.0% 
2 14 14.3% 
16 26 61.5% 
9 15 60.0% 
10 15 66.7% 
Data Analysis 25 12 Confirmed No 9 55.6% 
Farms 8 and 9 were ultimately considered as one farm data 
set since the horses from these 2 farms were combined into 
one population once the foals were weaned. Likewise, Farms 
22 and 23 were combined into one data set for the same 
13 
14 
15 
16 
Suspected 
Confirmed 
Suspected 
Confirmed 
Confirmed 
No 
No 
Confirmed 
13 15 86.7% 
9 15 60.0% 
9 15 60.0% 
11 11 100.0% 
reason. 30 17 Confirmed Confirmed 14 15 93.3% 
18 
19 
20 
21 
Confirmed 
Confirmed 
No 
Confirmed 
No 
No 
No 
Confirmed 
15 15 100.0% 
12 16 75.0% 
2 7 28.6% 
11 14 78.6% 
One way analysis of variance (ANOVAs) (Holm-Sidak 
method) was used to evaluate differences in ELISA titers 
between farms categorized based on their past EPE status. 
Post hoc t tests were performed to evaluate the differences 
between groups. Chi-square analyses were used to assess 
seroprevalence results. Calculated P valuess0.05 were con-
sidered to be statistically significant. 
22 and 23 
35 24 
Confirmed 
No 
Confirmed 
No 
24 29 82.8% 
10 15 66.7% 
Results 
In order to validate our ELISA, serum samples of varying 
EU were run in triplicate with an overall intra-assay CV of 40 
6.73 and inter-assay CV of9.60. For the standard curve, CVs 
ranged from 2.08 to 7.69 with a mean of 4.85 and the most 
dilute sample (1 :3840 dilution) had the highest CV. Addition-
ally, ELISA analysis of serial serum samples from L. intrac-
ellularis challenged weanlings demonstrated seroconversion 45 
on or before Day 20 post challenge with all weanlings obtain-
ing EU> 120 and a maximum of 7 46 EU while all nonchal-
lenged weanlings remained below 55 EU (Page eta!. 2011a). 
Provided in FIG. 1 are EU results for nonchallenged con-
trols and experimentally challenged weanlings (Page et a!. 50 
2011a), as well as clinically affected field cases from the 
study period (EU values shown are those found at the initial 
time of clinical presentation). Weanlings with clinical EPE 
had similar and, in some cases greater, serum antibody levels 
against L. intracellularis when compared with experimen- 55 
tally challenged weanlings. FIG. 2 includes EU results from 
all horses in the present study divided into 2 groups; study 
horses that failed to seroconvert (<55 EU) during the study 
and study horses that seroconverted (;;:55 EU) at any point 
during the study period but failed to show clinical signs of 60 
EPE. A number of the nonclinical, seropositive horses exhib-
ited very high EU. 
Overall, a total of 337 horses were included in the sera-
prevalence data set as they were present on the farms through 
at least November 2010. Of these 337 horses, a total of 229 65 
horses or 68.0% of the study population, tested positive (;;:55 
EU) for L. intracellularis-specific antibodies via the ELISA 
25 No No 
Farm specific seroprevalences ranged from 14.3-100% 
ELISA= enzyme-linked immunosorbent assay. 
15 53.5% 
with marked increases in seroconversion during the months 
of October 2010 and January 2011. As shown in FIG. 4, the 
majority of the seropositive animals for a givenmonthhadEU 
values in the range of55-119 EU. Beginning in October, there 
was an increase in the frequency of high titers (;;:120 EU) 
paralleling the increase in seroconversions noted in FIG. 3. 
Serological results from individual farms including past 
EPE status of the farm, EPE status during the study period and 
calculated seroprevalence for L. intracellularis are shown in 
Table 1 below. 
A total of 8 farms had confirmed cases of EPE during the 
study period and no farms had suspected but unconfirmed 
cases. Seven of these farms had already been classified as 
having previously confirmed cases of EPE and one had pre-
viously had suspected cases of EPE. Farms without a recent 
history of EPE had no cases during the study period. Calcu-
lated farm-specific seroprevalences ranged from 14.3% to 
100%. FIG. 5 shows the monthly seroconversionrate grouped 
by recent EPE history. Whereas those farms with a recent 
history of EPE (confirmed and suspected) had some horses 
seroconvert each month, the farms with no recent history of 
EPE (none) experienced several months in which zero or one 
horse seroconverted. Table 2 shows the overall average sera-
prevalence as well as the average positive and maximum titer 
values obtained from farms grouped by recent EPE status. 
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TABLE2 
Average seroprevalence, positive enzyme-linked immunosorbent assay 
(ELISA) units (EU) and maximum EU grouped by equine proliferative 
enteropathy CEPE) history 
Previous EPE cases Average seroprevalence Average positive EU Average max EU 
Confirmed 76.3%* (55.6-100%) 
Suspected 55.6% (20-86.7%) 
None 53.1% (14.3-73.3%) 
228.1 (85.5-378.9) 
218.0 (59.7-326.2) 
123.9** (59.5-175.6) 
1683.4 (193.8-4312.3) 
1604.6 (62.2-3319.4) 
453.9*** (55.6-904.1) 
*P < 0.05, 
**P < 0.079, 
***P < 0.056. 
Those farms with a confirmed history of EPE had signifi-
cantly (P<0.001) higher average seroprevalences compared 
with those with suspected or no recent cases of EPE. Addi-
tionally, the average EU (P=0.079) and average maximum 
EU values (P=0.056) were found to be lower on farms with no 
recent history ofEPE cases compared with the other groups. 
Moreover, the range of maximum titers is much smaller for 
the farms with no recent EPE cases. 
Discussion 
An ELISA method was used to characterize the serological 
response of Thoroughbred weanlings to L. intracellularis on 
central Kentucky farms. This ELISA method used column 
chromatography purified L. intracellularis, thus optimizing 
reproducibility, as evidenced by an overall intra-assay CV of 
6.73 and inter-assay CV of 9.60. Using this method, farm-
specific seroprevalences ranged from 14.3 to 100%. As such, 
these results are comparable with a past screening study in the 
central Kentucky region that used the IPMA method and 
showed an EPE endemic farm to have a seroprevalence of 
approximately 60% while a nonendemic farm had a sera-
prevalence of 17% (Page eta!. 2011 b). 
15 exhibited an increased antibody response, as was also 
detected in the L. intracellularis-challenged weanlings (Page 
eta!. 2011a), using this ELISA. While previous reports from 
the central Kentucky region suggest a single peak of exposure 
occurring during late fall/early winter (Frazer 2008; Page et 
20 a!. 2011 b), new evidence shows bimodal exposure occurring 
both in the fall and winter. These results correspond directly 
with anecdotal evidence indicating a large increase in the 
number of cases of EPE in this area during the months of 
January and February 2011. The reason for this increased 
25 incidence ofEPE has yet to be elucidated. Possible explana-
tions include changes in weather patterns, changes in man-
agement and increased exposure to the unknown reservoir, 
which could include clinically or subclinically affected 
horses. With respect to these possibilities, it should be noted 
30 that the summer and fall of 2010 experienced less rainfall 
when compared with average amounts for the region. Addi-
tionally, there were lower daily temperatures starting in 
November with increased amounts of both rain and snow, 
beyond what is normal for central Kentucky during the early 
35 winter months. 
Not surprisingly, seroprevalences corresponded well with 
the past history ofEPE cases on the farms. Significant differ-
ence between groups based on recent EPE history was seen 
with respect to average seroprevalence. Additionally, farms 
with no recent clinical cases of EPE had both lower average 40 
EU and average maximum EU values for their positive 
samples. One possible explanation is that farms with no his-
tory ofEPE cases probably had lower environmental burdens 
While the ELISA method affords ease of use and reliabil-
ity, the establishment of a cut-off value to separate negative 
and positive samples is critical. The current positive cut-off 
(;,;55 EU) utilized the average EU plus 3 s.d. from values 
obtained for nonchallenged weanlings, reported elsewhere 
(Page eta!. 2011a), and differentiated between known serop-
ositve and seronegative horses. Twelve field cases evaluated 
using the ELISA had high levels of L. intracellularis-specific 
antibodies, equalling or surpassing those EU detected in the 
experimentally challenged weanlings. Also noted were sev-
eral nonclinically affected weanlings with markedly elevated 
of L. intracellularis resulting in fewer horses being exposed 
to the bacterium (lower seroprevalence) and less antigenic 45 
stimulation per exposure (lower EU values). Evidence for this 
assertion is provided by the nonendemic farm from the pre-
vious study (Page eta!. 2011 b), which is also represented in 
the current study (Farm 15). While originally considered 
nonendemic, the farm has since reported suspected cases of 50 
EPE and was re-classified for the purpose of this study. 
Accordingly, the farm's seroprevalence was found to be 60% 
with an average positive EU of326.2 and a maximum EU of 
3319.4. 
EU values. These could be indicative of a successful immu-
nological response to infection or a subclinical case that was 
not detected by the farm; both situations were observed in the 
previous challenge study (Page eta!. 2011a). As such, these 
findings provide further evidence that the new ELISA suc-
cessfully detects antibodies to L. intracellularis in clinical 
and nonclinically affected horses. 
There were 2 inherent limitations with the design of this 
Given that the epidemiology of EPE remains poorly 
defined, these data begin to indicate that relative burdens of L. 
intracellularis in the environment may explain why certain 
farms have an endemic problem with EPE. 
Monitoring ofweanlings by the enrolled farms ultimately 
identified 8 farms with confirmed cases of EPE during the 
study period from August 2010 to February 2011. Perhaps not 
surprisingly these 8 farms represented only those with prior 
confirmed or suspected cases ofEPE (7 and 1, respectively). 
While definitive ante mortem diagnosis ofEPE remains con-
troversial, elevated L. intracellularis-specific antibody levels 
are commonly identified in clinically affected horses (Frazer 
2008; Page et a!. 2011 b). These confirmed cases likewise 
55 study. First, there was an overrepresentation of farms with 
confirmed or suspected cases of EPE in the data set. This 
likely reflected the fact that those farms with a prior history of 
what they consider to be a frustrating disease were more 
willing to participate and provide data. Additionally, the 
60 stigma associated with this disease in central Kentucky may 
have contributed to the large number of farms that declined to 
participate due to fears that their status with respect to L. 
intracellularis and EPE would become public. As such, the 
overall seroprevalence of 68% should not be considered rep-
65 resentative of the equine population in this region without 
further, randomised sampling. Nevertheless, 20% of the 
horses surveyed came from farms with no recent history of 
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EPE and we reported both farm-specific and group-specific 
seroprevalences. The other limitation and potential source for 
error revolves around the possibility of cross-reaction of this 
ELISA with other bacteria. Phylogenetic studies have found 
that while L. intracellularis appears to be a member of unique 
pathogens (Dale eta!. 1998), more recent work has shown L. 
intracellularis shares similarities with some rickettsial fami-
lies (Schmitz-Esser et a!. 2008). As such, potential cross-
reactivity between other organisms cannot be excluded with-
out further testing. However, work to validate the ELISA 10 
from which the method reported here was adapted failed to 
detect any cross-reactivity between L. intracellularis and 
related bacterial species (Wattanaphansak et a!. 2008). 
By screening a large population of central Kentucky Thor- 15 
oughbreds using a newly validated and equine-adapted 
ELISA, a high seroprevalence for L. intracellularis-specific 
antibodies was detected with variable farm-specific sera-
prevalences. Previous history ofEPE on the farms was asso-
ciated with significant differences in average seroprevalence 20 
indicating lower levels of exposure are present on farms with 
no history of EPE. Additionally, a bimodal, seasonal distri-
bution of exposure was documented. The high farm-specific 
seroprevalences and bimodal distribution of exposure to L. 
intracellularis were unexpected and suggest that farms with a 25 
previous history of EPE remain at risk due to heightened 
exposure levels beyond early winter, as has been suggested 
previously. 
It will now be clear to one of ordinary skill in the art that the 
present method and system have features and advantages over 30 
prior techniques including sensitivity and specificity. Varia-
tions to the specific process conditions and experimental con-
ditions described herein may be modified or substituted as 
appropriate and understood by one of ordinary skill in the art, 35 
consistent with the present disclosure. This includes modifi-
cation of the ELISA procedure to incorporate other species-
specific reagents such that the ELISA can test samples origi-
nating from a variety of other species including, but not 
limited to, swine, hamsters, rabbits, mice, rats, non-human 40 
primates, human, raccoons, birds and insects. 
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The invention claimed is: 
1. A method for testing an exposure to a Law sonia intrac-
ellularis in a subject, said method comprising: 
purifYing whole Lawsonia intracellularis from host cells 
and host debris using ion-exchange chromatography on 
whole intact L. intracellularis produced in or on a suit-
40 
6. The method of claim 4, further comprising centrifuging 
a blood sample from the subject to produce the serum. 
7. A method for diagnosing a L. intracellularis infection or 
exposure in a subject, said method comprising: 
acquiring a serum sample from a subject; 
introducing the serum sample to an antigen substrate com-
prising purified L. intracellularis, produced from host 
cells and host debris using ion-exchange chromatogra-
phy on whole L. intracellularis, adhered to a suitable 
material, wherein the purified L. intracellularis are 
whole L. intracellularis whole cells produced by first 
centrifugation of L. intracellularis host cells and patho-
gen host debris prior to the ion-exchange; and 
detecting a presence of L. intracellularis-specific antibod-
ies in the serum against the antigen substrate bound to 
the antigen substrate, thereby indicating a L. intracellu-
laris exposure or infection in the subject. 
8. The method of claim 7, wherein acquiring the serum 
sample comprises centrifuging a blood sample from the sub-
ject to produce the serum. 
9. The method of claim 7, wherein the ion-exchange chro-
matography comprises DEAE chromatography. 
* * * * * 
